Compounds > cheliensisin a
Page last updated: 2024-08-03 19:53:20

cheliensisin a

Description

cheliensisin A: structure in first source [MeSH]

Cross-References

ID SourceID
PubMed CID56683717
CHEMBL ID1818734
SCHEMBL ID15937093
MeSH IDM0490958

Synonyms (3)

Synonym
cheliensisin a
CHEMBL1818734
SCHEMBL15937093

Bioassays (6)

Assay IDTitleYearJournalArticle
AID613816Cytotoxicity against human A549 cells after 48 hrs by MTT assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
ISSN: 1768-3254		Development of novel conformation-constrained cytotoxic derivatives of cheliensisin A by embedment of small heterocycles.
AID613814Cytotoxicity against human HL60 cells after 48 hrs by MTT assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
ISSN: 1768-3254		Development of novel conformation-constrained cytotoxic derivatives of cheliensisin A by embedment of small heterocycles.
AID613817Cytotoxicity against human SKBR3 cells after 48 hrs by MTT assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
ISSN: 1768-3254		Development of novel conformation-constrained cytotoxic derivatives of cheliensisin A by embedment of small heterocycles.
AID613818Cytotoxicity against human PANC1 cells after 48 hrs by MTT assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
ISSN: 1768-3254		Development of novel conformation-constrained cytotoxic derivatives of cheliensisin A by embedment of small heterocycles.
AID613819Chemical stability of the compound in 0.1 M phosphate buffer at pH 7.0 at 0.1 mg/mL after 12 hrs by HPLC analysis2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
ISSN: 1768-3254		Development of novel conformation-constrained cytotoxic derivatives of cheliensisin A by embedment of small heterocycles.
AID613815Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
ISSN: 1768-3254		Development of novel conformation-constrained cytotoxic derivatives of cheliensisin A by embedment of small heterocycles.

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (25.00)29.6817
2010's6 (75.00)24.3611
2020's0 (0.00)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
serine
1
L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid;
serine zwitterion;
serine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		2014201410.0high000010
h 89
1
N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide2005200519.0high000100
epidermal growth factor
2
2013201410.5high000020
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Bladder Cancer0
2
201620187.0medium000020
Cancer of Colon0
2
2008201413.0medium000110
Cancer of Lung0
1
2008200816.0low000100
Cell Transformation, Neoplastic0
2
2013201410.5medium000020
Colonic Neoplasms0
2
2008201413.0medium000110
Lung Neoplasms0
1
2008200816.0low000100
Urinary Bladder Neoplasms0
2
201620187.0medium000020

Dosage (1)

ArticleYear
Lyophilized Cheliensisin A submicron emulsion for intravenous injection: characterization, in vitro and in vivo antitumor effect.
International journal of pharmaceutics, , Jun-05, Volume: 357, Issue:1-2		2008